USA - New York Stock Exchange - NYSE:PHR - US71944F1066 - Common Stock
The current stock price of PHR is 20.29 USD. In the past month the price decreased by -8.89%. In the past year, price decreased by -6.63%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 31.27 | 39.67B | ||
| DOCS | DOXIMITY INC-CLASS A | 28.01 | 8.65B | ||
| WAY | WAYSTAR HOLDING CORP | 25.63 | 6.57B | ||
| HTFL | HEARTFLOW INC | N/A | 2.34B | ||
| CERT | CERTARA INC | 18.44 | 1.47B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.35B | ||
| SDGR | SCHRODINGER INC | N/A | 1.30B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.10B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 635 | 1.08B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 7.74 | 919.86M | ||
| HSTM | HEALTHSTREAM INC | 35.68 | 719.79M | ||
| CTEV | CLARITEV CORP | N/A | 561.19M |
Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The company is headquartered in Wilmington, Delaware and currently employs 2,082 full-time employees. The company went IPO on 2019-07-18. The firm's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The firm's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
PHREESIA INC
1521 Concord Pike, Suite 301 Pmb 221
Wilmington DELAWARE 27601 US
CEO: Chaim Indig
Employees: 2082
Phone: 18886547473
Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The company is headquartered in Wilmington, Delaware and currently employs 2,082 full-time employees. The company went IPO on 2019-07-18. The firm's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The firm's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
The current stock price of PHR is 20.29 USD. The price decreased by -1.27% in the last trading session.
PHR does not pay a dividend.
PHR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
PHREESIA INC (PHR) will report earnings on 2025-12-08, after the market close.
You can find the ownership structure of PHREESIA INC (PHR) on the Ownership tab.
The outstanding short interest for PHREESIA INC (PHR) is 6.01% of its float.
ChartMill assigns a fundamental rating of 4 / 10 to PHR. While PHR has a great health rating, there are worries on its profitability.
Over the last trailing twelve months PHR reported a non-GAAP Earnings per Share(EPS) of -0.42. The EPS increased by 62.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.89% | ||
| ROE | -8.07% | ||
| Debt/Equity | 0.02 |
20 analysts have analysed PHR and the average price target is 34.48 USD. This implies a price increase of 69.92% is expected in the next year compared to the current price of 20.29.
For the next year, analysts expect an EPS growth of 96.66% and a revenue growth 13.85% for PHR